Longevity Medical Institute adds intranasal regenerative therapy for neurological care

Longevity Medical Institute in San José del Cabo has launched a regenerative neurology program that uses an intranasal delivery platform to move therapies toward the brain without a lumbar puncture. The institute says the approach expands options for selected neurological conditions alongside its existing intrathecal, intravenous and other physician-guided treatments.

Why it matters: - Longevity Medical Institute is adding a non-invasive option for delivering regenerative therapies aimed at the brain. - The intranasal platform is intended to give physicians another route to treat selected neurological conditions when intrathecal administration is not the best fit. - The launch could broaden access to brain-directed regenerative care for patients who want to avoid a lumbar puncture.

What happened: - Longevity Medical Institute announced the launch of its Regenerative Neurological Therapy Program on July 23, 2026. - The program includes an advanced intranasal delivery platform designed to transport regenerative therapies through the nasal cavity toward the brain. - The institute is based in San José del Cabo, Baja California Sur, Mexico. - Dr. Kirk Sanford, founder and CEO, said the platform expands personalized treatment by adding non-invasive intranasal administration alongside intrathecal delivery.

The details: - The blood-brain barrier blocks many therapeutic compounds from reaching the central nervous system. - Intrathecal administration delivers therapies into cerebrospinal fluid but requires a lumbar puncture. - The new platform uses nose-to-brain delivery technology described in the scientific literature. - The system is engineered to target the upper nasal cavity near the olfactory region, rather than the lower nasal passages targeted by standard sprays. - Research has shown that compounds delivered to the olfactory region may travel toward the brain along the olfactory and trigeminal nerve pathways. - The platform uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer generates microscopic aerosol droplets and delivers them gradually over several minutes. - The controlled delivery is designed to increase contact time in the olfactory region, reduce medication loss into the throat and improve delivery consistency. - Longevity Medical Institute uses the platform only for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes and selected therapeutic peptides. - Treatment recommendations come from a multidisciplinary physician team after a neurological evaluation that may include advanced imaging, laboratory testing, neurological examination and review of medical history. - The broader neurological program also includes intravenous regenerative therapies, intrathecal administration in the institute's licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging and multidisciplinary physician care. - The institute says treatment decisions are based on physician evaluation, published scientific evidence, patient-specific factors and clinical judgment. - The program information is available here.

Between the lines: - The launch positions intranasal delivery as a practical middle ground between standard nasal treatment and more invasive intrathecal procedures. - The institute is leaning on published human research around MSCs and exosomes to support a broader regenerative neurology offering. - The company cites encouraging safety findings across multiple neurological conditions, but the release also acknowledges that larger randomized trials are still needed. - That framing suggests the platform is being presented as an evidence-informed option, not a replacement for established care.

What's next: - Longevity Medical Institute expects continued clinical research to clarify which patients may benefit most and how durable treatment responses may be. - The institute will continue offering individualized recommendations based on diagnosis, clinical findings and treatment goals. - Regenerative neurological therapies remain a fast-growing area of translational medicine, according to the release.

The bottom line: - Longevity Medical Institute is expanding its neurology toolkit with a less invasive brain-targeted delivery option that could widen treatment choices while broader clinical evidence continues to develop.